Clinical trials: Sequela
Post-COVID-19 Syndrome
Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
This study is a Phase 2, 24-week, randomized, prospective, double-blind, multicenter study in patients experiencing neuropsychiatric symptoms and functional impairment in the course of PASC.
- Trial name
- NCT05497089
- Testing
- Temelimab 54mg/kg
- Where
- 14 sites in Italy, Spain and 1 more
- Volunteers
- 203 people
- Sponsor
- GeNeuro SA
Stroke Sequelae, Cognitive Impairment
Remote Bimanual Virtual Rehabilitation Post CVD
The aim of the study is to develop the BrightBrainer G (grasp), a game-based upper-extremity motor and cognitive rehabilitation system using custom virtual reality simulations.
- Conditions
- Stroke Sequelae, Cognitive Impairment, Depression
- Trial name
- NCT04713384
- Testing
- Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Grigore Burdea
Stroke Sequelae, Stroke
Multiple Dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability of NDC-002 in Healthy Volunteers
An Open-label, One-sequence, Three-period, Multiple-dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability between NDC-002A/NDC-002B and NDC-002C in Healthy Volunteers
- Trial name
- NCT06090474
- Testing
- NDC-002
- Where
- South Korea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Dr. Noah Biotech Inc.
Glaucoma
5 Years Long Term Results After Standalone CyPass-Implantation
This study evaluates the results of all clinically relevant findings of glaucoma diagnostics 5 Years after stent-implantation concerning the safety and effectiveness of the cypass stent procedure.
- Trial name
- NCT03114059
- Testing
- Glaucoma diagnostics
- Where
- Germany
- Volunteers
- 230 people
- Sponsor
- Dietrich-Bonhoeffer-Klinikum
Sequelae of Viral Hepatitis, Transplantation Infection
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
A Phase 2 study to evaluate safety, pharmacokinetics and efficacy of Hepatitis C Immune Globulin Intravenous (human) [Civacir(TM)] for preventing or reducing the impact of recurrent HCV infection following liver transplantation.
- Conditions
- Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation
- Trial name
- NCT00473824
- Testing
- Hepatitis C Immune Globulin Intravenous (Human) 5%
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- ADMA Biologics, Inc.
Ischemic Stroke in the Sequelae Stage
ALT001 in Patients With Ischemic Stroke in the Sequelae Stage
This is a phase II, randomized, double-blind, placebo-controlled, multicentre clinical study to evaluate the efficacy and safety of ALT001 in patients with ischemic stroke in the sequelae stage (≥180 days and ≤5 years after the…
- Trial name
- NCT07841496
- Testing
- ALT001
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Darwin Origin (Hubei) Biopharmaceutical Co., Ltd.
Post Polio Syndrome, PPS
Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)
The primary objective was to assess the effect of Xepol compared to placebo on physical health and on muscle strength in subjects with post-polio syndrome.The secondary objective was to assess the effect of Xepol compared to…
- Trial name
- NCT00160082
- Testing
- Xepol
- Where
- 4 sites in Sweden
- Volunteers
- 124 people
- Sponsor
- Calliditas Therapeutics AB
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving muscle function (metabolism) following moderate exercise in subjects with fatigue-Predominant Post-Acute…
- Trial name
- NCT05152849
- Testing
- AXA1125
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- Axcella Health, Inc
COVID-19, SAR
(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC
Coronavirus disease (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents a major threat to human health.
- Trial name
- NCT04777981
- Testing
- CBDRA60 supplement
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Anewsha Therapeutics Inc.
Stroke, Stroke, Ischemic
MLC1501 Study Assessing Efficacy in STROke Recovery
This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a…
- Conditions
- Stroke, Stroke, Ischemic, Strokes Thrombotic, Stroke Sequelae
- Trial name
- MAEStro (NCT05046106)
- Testing
- MLC1501
- Volunteers
- 540 people
- Sponsor
- Moleac Pte Ltd.
Invasive Group B Streptococcus Disease, Group B Streptococcus
Comprehensive Outcomes Monitoring for Peri- and Postnatal Invasive Group B Strep Sequelae (COMPPASS) Registry
The goal of this registry is to collect and store important medical and non-health information on children from 0 to 18 years of age affected by early- (up to 24 hours after birth) and late-onset (up to 90 days after birth)…
- Conditions
- Invasive Group B Streptococcus Disease, Group B Streptococcus, Group B Streptococcal Infection, Group B Streptococcus (GBS) Disease
- Trial name
- COMPPASS (NCT06896526)
- Volunteers
- 10,000 people
- Sponsor
- Precia Group